Boston Scientific (NYSE:BSX) Hits New 52-Week Low – Time to Sell?

Boston Scientific Corporation (NYSE:BSX)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $43.83 and last traded at $44.03, with a volume of 4208746 shares traded. The stock had previously closed at $44.23.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BSX. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research report on Thursday, May 28th. Barclays reduced their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $77.00 price target on shares of Boston Scientific in a research note on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Stock Performance

The stock’s 50-day moving average price is $52.04 and its 200 day moving average price is $70.28. The firm has a market cap of $63.38 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 0.83 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the business earned $0.75 EPS. The company’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has initiated a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In related news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 9,800 shares of company stock worth $554,012. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Institutional investors have recently added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the 4th quarter valued at about $26,000. Bangor Savings Bank lifted its stake in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific during the first quarter worth about $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.